Will venetoclax be included in medical insurance in 2024?

Venetoclax (Venetoclax) is a targeted anti-cancer drug mainly used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). It works by inhibiting the function of BCL-2 (BCL-2) protein, which is highly expressed in cancer cells and prevents natural cell apoptosis. By inhibiting this protein, venetoclax prompts cancer cells to enter the apoptosis process, thereby reducing the number of malignant cells and achieving therapeutic purposes.

The main advantage of venetoclax is that it targets specific molecular targets, killing cancer cells with precision and having less impact on healthy cells. This makes venetoclax a valuable treatment option in certain patients, especially older patients, who cannot tolerate traditional chemotherapy. It is often combined with other anticancer drugs to enhance their effectiveness.

Venetoclax has been officially launched in the Chinese market and has been included in the national medical insurance directory. This is important good news for patients, as the high cost of anticancer drugs often puts them out of reach. After being included in medical insurance, patients can enjoy medical insurance reimbursement when using venetoclax, reducing treatment costs. The specific reimbursement ratio will vary according to the type of medical insurance and regional policies where the patient lives. Generally, patients can consult the local medical insurance department or hospital pharmacy for detailed reimbursement information.

In addition, the use of venetoclax needs to be carried out strictly under the guidance of a doctor, especially in the early stages of treatment. The doctor will develop a gradually increasing dosage plan based on the patient's specific condition and constitution to reduce the risk of potential side effects. For price comparisons and treatment options at home and abroad, patients can also make reasonable choices based on their personal financial situation and medical insurance reimbursement policies.